Literature DB >> 25563217

Determining the persistence of maternally acquired antibodies to hepatitis A and varicella zoster during the first 2 years of life in Turkey.

Fırat Begde1, Filiz Simsek Orhon, Devran Gerceker, Betul Ulukol, Seda Topcu, Sevgi Baskan.   

Abstract

UNLABELLED: Vaccination should be timed to take into account the potential interference of maternal antibodies. The purpose of this study was to determine the persistence of maternally acquired antibodies to hepatitis A and varicella zoster in a group of healthy infants between 6 and 24 months of age. These infants were divided into four groups according to the age at the time of follow-up visits. The study group consisted of infants who were brought to the 6-month follow-up visit (group 1, n=100), 12-month follow-up visit (group 2, n=99), 18-month follow-up visit (group 3, n=59), and 24-month follow-up visit (group 4, n=59). Hepatitis A, varicella IgG, and IgM antibodies were analyzed qualitatively. Hepatitis A IgG seropositivity was determined as 71 % in group 1, 41.4 % in group 2, 0 % in group 3, and 8.5 % in group 4 (p<0.001). Varicella IgG seropositivity was found to be 5 % in group 1, 4 % in group 2, 4 % in group 3, and 1 % in group 4 (p>0.05).
CONCLUSION: We found that maternal hepatitis A antibodies in children disappear between 12 and 18 months, whereas maternal varicella antibodies substantially diminish following the sixth month. Therefore, the vaccination timing should be based on factors such as the interference of maternal antibodies, disease susceptibility period, and immune maturation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563217     DOI: 10.1007/s00431-014-2484-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  31 in total

1.  Hepatitis A vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-02-04

Review 2.  Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants.

Authors:  Claire Anne Siegrist
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

3.  Placental transport of maternal immunoglobulin G.

Authors:  M Palfi; A Selbing
Journal:  Am J Reprod Immunol       Date:  1998-01       Impact factor: 3.886

4.  Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels.

Authors:  Martin W G Brinkhof; Orlando Mayorga; Jürgen Bock; Ulrich Heininger; Christian Herzog
Journal:  Vaccine       Date:  2013-01-14       Impact factor: 3.641

5.  Seroprevalence of varicella-zoster virus in the German population.

Authors:  P Wutzler; I Färber; S Wagenpfeil; H Bisanz; A Tischer
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

6.  Kinetics of maternal antibodies against rubella and varicella in infants.

Authors:  E Leuridan; N Hens; V Hutse; M Aerts; P Van Damme
Journal:  Vaccine       Date:  2010-06-15       Impact factor: 3.641

Review 7.  Varicella-zoster virus.

Authors:  A M Arvin
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

8.  Decline of maternal hepatitis A virus antibody levels in infants.

Authors:  A De Silvestri; M A Avanzini; V Terulla; S Zucca; F Polatti; C Belloni
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

Review 9.  Effect of maternal antibodies on the infant immune response.

Authors:  W Paul Glezen
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

10.  Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.

Authors:  Sandra Waaijenborg; Susan J M Hahné; Liesbeth Mollema; Gaby P Smits; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Jacco Wallinga
Journal:  J Infect Dis       Date:  2013-05-08       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.